There’s no single cause for triple-negative breast cancer. While we know mutated DNA makes cells divide uncontrollably, why it triggers in a specific person remains unknown. Identified genetic, biological, and reproductive risk factors don’t guarantee diagnosis, but knowing them helps guide personal screening choices and genetic testing for families.
According to Dr. Sandeep Nayak, Best Cancer Treatment in Bangalore, “TNBC tends to develop in younger women, in women of African ancestry, and in BRCA1 mutation carriers at higher rates than other breast cancer subtypes. That pattern tells us something about the biology of the tumour even if we can’t point to one single cause. It also tells us who deserves closer surveillance and earlier BRCA testing.”
Unsure about your individual risk factors or genetic profile for triple-negative breast cancer?
What Raises the Risk of Triple-Negative Breast Cancer?
BRCA1 mutations are the strongest known genetic link
Women who carry a germline BRCA1 mutation are significantly more likely to develop TNBC specifically, not just breast cancer generally. Around 70% of BRCA1-associated breast cancers are triple-negative. This is different from BRCA2, which is more associated with hormone receptor-positive breast cancer. BRCA1 testing matters in TNBC not only for treatment decisions but for the patient’s family members who may carry the same mutation.
Younger age at diagnosis
TNBC is diagnosed in younger women far more often than hormone receptor-positive breast cancer, which tends to be a disease of older women. Women under 40 with breast cancer are more likely to have TNBC than older women with the same diagnosis. This age pattern is part of what makes TNBC distinct biologically, not just clinically.
African ancestry
Women of African descent develop TNBC at higher rates than women of European or Asian ancestry. The reasons are incompletely understood and likely involve a combination of genetic, biological, and possibly hormonal factors. The disparity is real and documented across multiple populations, and it is relevant to how screening and genetic testing are prioritised in these communities.
Reproductive factors
Having a first child after 30, or never having children, is associated with higher overall breast cancer risk and appears to have a specific relationship with triple-negative breast cancer risk. Breastfeeding appears to be somewhat protective against TNBC specifically, separate from its effect on other breast cancer subtypes.
Premenopausal status
TNBC disproportionately affects premenopausal women. The hormonal environment of the premenopausal period appears to influence the type of breast cancer that develops, though the mechanism isn’t fully established.
Prior radiation to the chest
Women who received chest radiation in their teens or twenties, typically for Hodgkin lymphoma, have an elevated lifetime breast cancer risk, and some studies suggest a higher proportion of those cancers are hormone receptor-negative.
Why TNBC Behaves Differently From Other Breast Cancers?
- Why Standard Therapies Don’t Work: The absence of estrogen, progesterone, and HER2 receptors means hormone-blocking drugs (like tamoxifen) and HER2-targeted therapies (like trastuzumab) have no foothold to target the cancer cells.
- Targeted Treatment Options: Management relies on chemotherapy to target rapidly dividing cells, immunotherapy (such as pembrolizumab) to activate the body’s immune response, and PARP inhibitors for patients with specific BRCA gene mutations.
- Biology Dictates Strategy: Tumor biomarkers directly determine your care path—for example, BRCA status unlocks PARP inhibitors, while PD-L1 expression predicts better responses to immunotherapy.
(For a complete picture of how treatment pathways are established based on biology, read our detailed guide on triple-negative breast cancer
Why Choose MACS Clinic for Triple-Negative Breast Cancer?
Dr. Sandeep Nayak’s team at MACS Clinic reviews every TNBC case through a tumour board before any plan is confirmed. BRCA testing, PDL1 status, and neoadjuvant response assessment are all completed before surgical planning begins. The operation is planned around what the tumour looks like after systemic treatment, not what it looked like at the time of diagnosis.
TNBC decisions are time-sensitive. Getting the sequence right requires all disciplines reviewing the case together, not separate consultations that don’t communicate. Those who want to discuss their diagnosis can reach the team at +91 8035740000.
FAQs
Is TNBC hereditary?
Not always, but BRCA1 mutations are strongly associated with TNBC specifically. All TNBC patients should have germline BRCA testing regardless of family history, because the mutation rate is higher than most people assume.
Can lifestyle choices cause TNBC?
No single lifestyle factor causes TNBC. Breastfeeding appears somewhat protective. First pregnancy after 30 is associated with modestly higher risk. But the relationship is not as direct as, say, smoking and lung cancer.
Why does TNBC affect younger women more?
The honest answer is that the mechanism isn’t fully established. Premenopausal hormonal environment, BRCA1 mutation rates in younger patients, and biological differences in tumour development across age groups all appear to play a role.
.
Does finding the cause change how TNBC is treated?
Yes, in specific cases. BRCA mutation status determines whether PARP inhibitors are available. PDL1 expression determines how immunotherapy is used. The biological cause of the individual patient’s TNBC shapes which parts of the treatment toolkit apply to them.
References
- National Cancer Institute. Triple-Negative Breast Cancer. https://www.cancer.gov/types/breast/triple-negative-fact-sheet
- Plasilova ML et al. Features of triple-negative breast cancer: Analysis of 38,813 cases from the National Cancer Database. Medicine, 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457999/
Disclaimer:This content is published for educational and informational purposes only.